Targeting the CDK-RB-E2F axis for cancer therapy is becoming an increasingly attractive strategy due to recent advances in developing specific small molecule inhibitors targeting either CDK4/6 or E2Fs114,115. This evidence concerns the gene RB1 and cancer.